Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX003 MAD Study in Psoriasis
NCT02630901Phase 1Completed
- Sponsor
- Prothena Corporation
- Start
- Mar 2016
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing PRX003 with Placebo (2 arms). Primary endpoints: Safety and tolerability as determined by number of subjects with adverse events at 6 months and Determination of pharmacokinetics parameters at 20 weeks. Started Mar 2016; status: completed.
02
Drugs
Imaprelimab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02630901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630901.